ArticleFrontiers in neurology2025
Efficacy of endovascular treatment for patients with acute large vessel occlusion stroke from the Western Sichuan Plateau and machine learning prediction models: a prospective study protocol.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- High-altitude exposure and ischemic stroke: pathophysiological mechanisms and current perspectives.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Stroke is the second leading cause of death and the third leading cause of disability among non-communicable diseases globally. The prevalence, incidence, and mortality rates of stroke are higher in high-altitude regions compared to lowland areas. However, compared to plain areas, the efficacy of endovascular therapy for large vessel occlusive acute ischemic stroke (LVO-AIS) in high-altitude regions remains unclear. Methods and Design: This study is a multicenter, prospective, endpoint-blinded cohort study. From January 2025 to December 2027, a total of 1,052 patients with acute large vessel occlusion ischemic stroke (LVO-AIS) from the Western Sichuan Plateau will be prospectively enrolled, including those who receive endovascular treatment and those who do not. Baseline characteristics and endovascular treatment details will be documented. Treatment decisions are guided by clinical practice guidelines, taking into account high-altitude real-world constraints such as patient or proxy refusal and delays in interhospital transfer. Medical records will be established for each patient, and a 180-day follow-up will be conducted. The primary outcome was the proportion of patients achieving functional independence [modified Rankin scale (mRS) range from 0 to 2] at 90 days. The secondary outcomes included the mRS score at 90 days, early neurological improvement rate [defined as a National Institutes of Health Stroke Scale (NIHSS) score of 0-2 or a reduction of ≥8 points from baseline within 24 h of enrollment], changes in NIHSS scores between day 7 ± 1 or discharge and baseline, quality of life as assessed by the five-level EuroQol five-dimensional questionnaire at 90 days, and cognitive function at 180 days will be assessed using mini-mental state examination and montreal cognitive assessment scores. Imaging outcomes will include the rate of successful reperfusion (defined as a modified Thrombolysis in Cerebral Infarction score ≥2b) and infarct volume measured within 5-7 days. Statistical analysis and fused optimized multimodal learning were blinded to the group assignments. Conclusion: This study aims to evaluate the efficacy of endovascular treatment compared with standard medical therapy in patients with LVO-AIS in the Western Sichuan Plateau and to develop an artificial intelligence-based prognostic model to refine treatment strategies for this and other high-altitude regions. Clinical trial registration: https://www.chictr.org.cn/showproj.html?proj=241870, ChiCTR2400092762.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.